VAIA
PACB icon

Virtus Alternative Investment Advisers’s Pacific Biosciences PACB Stock Holding History

Virtus Alternative Investment Advisers’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-6,939
Closed -$21K – 286
2020
Q1 		$21K Buy
6,939
+5,234
+307% +$21.4K 0.29% 201
2019
Q4 		$9K Buy
+1,705
New +$8.67K 0.14% 160

Other funds holding PACB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KLCMU
Kite Lake Capital Management (UK) London, United Kingdom $125M AUM 198.01% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Virtus Alternative Investment Advisers's PACB Position: Q2 2020 in Review

Virtus Alternative Investment Advisers sold out of Pacific Biosciences (PACB) in Q2 2020, closing a stake of 6,939 shares — an estimated $21K sold.

Virtus Alternative Investment Advisers first reported a position in PACB in Q4 2019 and held it in 2 quarters. The position peaked at $21K in Q1 2020. 151 funds tracked by Wall St. Rank hold PACB as of Q2 2020.

  • Virtus Alternative Investment Advisers reported no remaining Pacific Biosciences position as of Q2 2020 after selling out during the quarter.
  • Virtus Alternative Investment Advisers sold 6,939 Pacific Biosciences shares in Q2 2020, an estimated $21K.
  • Virtus Alternative Investment Advisers first reported a position in Pacific Biosciences in Q4 2019 and held it in 2 quarters.
  • Virtus Alternative Investment Advisers's Pacific Biosciences position peaked at $21K in Q1 2020.
  • 151 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2020.

Based on Virtus Alternative Investment Advisers's 13F filing for Q2 2020, filed 5 Aug 2020.